Loading clinical trials...
Loading clinical trials...
To assess the efficacy and safety of using recombinant humanized anti-CD25 monoclonal antibody injection as a prophylactic strategy for reducing the incidence of severe acute graft-versus-host disease...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Institute of Hematology & Blood Diseases Hospital, China
NCT07070674 · Acute Graft-versus-Host Disease
NCT06294691 · Acute Graft-versus-host Disease
NCT06936566 · Acute Graft-versus-host Disease, Allogeneic Bone Marrow Transplantation, and more
NCT02611180 · Acute Graft-versus-host Disease, Acute GVHD, and more
NCT06075706 · Steroid-refractory Acute Graft-versus-host Disease
Institute of Hematology & Blood Diseases Hospital
Tianjin, Tianjin Municipality
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions